Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use
NCT ID: NCT01648491
Last Updated: 2017-01-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1 participants
INTERVENTIONAL
2011-10-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autologous Muscle Derived Cells for Underactive Bladder
NCT02463448
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
NCT00847535
Effect of Peri-Urethral Stimulation on Intra-Urethral Pressure
NCT05900570
Autologous Muscle Derived Stem Cells Transplantation in Urine Incontinency
NCT01963455
Treatment of Stress Urinary Incontinence in Women With Autologous Adipose-derived Mesenchymal Stem Cells
NCT04446884
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stem Cell treatment
Muscle Biopsy and Injection of autologous stem cells
Muscle Biopsy
Biopsy of thigh muscle to obtain stem cell core.
Injection of autologous stem cells
After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Muscle Biopsy
Biopsy of thigh muscle to obtain stem cell core.
Injection of autologous stem cells
After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* failed urinary incontinence (UI) treatments
78 Years
82 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
William Beaumont Hospitals
OTHER
Kenneth Peters, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kenneth Peters, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kenneth M Peters, MD
Role: PRINCIPAL_INVESTIGATOR
William Beaumont Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beaumont Hospital - Royal Oak
Royal Oak, Michigan, United States
William Beaumont Hospital
Royal Oak, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.